The discovery of several altered signaling pathways associated with ccRCC has opened new opportunities and strategies in the treatment of ccRCC, especially the targeted inhibition of molecules involved in VEGF and mTOR pathways (11–12). This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.